大师作文网请大家帮忙翻译一下这个段落
来源：学生作业帮 编辑：大师作文网作业帮 分类：英语作业 时间：2024/11/20 19:05:09
请大家帮忙翻译一下这个段落
Study population
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago, IL, USA). 17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville, NJ, USA). These 17 women had endometriosis (seven), uterine fibroids (three), sinusitis (four), rheumatoid arthritis (two), and ulcerative colitis (one) and were included in the masked validation set. Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria: at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer. BRCA1/2 status was not made available to this analysis under the conditions of anonymisation. The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer. Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1). All major epithelial subtypes of ovarian cancer were represented, and six of the cancer samples were from women with stage I disease, which mirrors the distribution of stage I ovarian cancer in the community. Reported oral contraceptive use and parity was not different between the groups. The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set. These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]), including only those with stage I cancers (57 [35–75]). On the basis of the age distribution, premenopausal and postmenopausal women were ally represented in both groups, thus menopausal status should not have been a discriminator in the detection algorithm.
生物或化学相关,谢绝翻译工具
Study population
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago, IL, USA). 17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville, NJ, USA). These 17 women had endometriosis (seven), uterine fibroids (three), sinusitis (four), rheumatoid arthritis (two), and ulcerative colitis (one) and were included in the masked validation set. Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria: at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer. BRCA1/2 status was not made available to this analysis under the conditions of anonymisation. The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer. Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1). All major epithelial subtypes of ovarian cancer were represented, and six of the cancer samples were from women with stage I disease, which mirrors the distribution of stage I ovarian cancer in the community. Reported oral contraceptive use and parity was not different between the groups. The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set. These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]), including only those with stage I cancers (57 [35–75]). On the basis of the age distribution, premenopausal and postmenopausal women were ally represented in both groups, thus menopausal status should not have been a discriminator in the detection algorithm.
生物或化学相关,谢绝翻译工具
杜绝机译,请放心采用.
Study population
研究人群
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago,IL,USA).17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville,NJ,USA).100个对照样本（50个用于初步分析,50个用于隐蔽的分析）由西北大学医院（美国伊利诺斯州芝加哥）的卵巢癌早期检测计划（NOCEDP）的诊所提供.另外17个来自于没有受癌症影响的、姓名不详的妇女的样本则由西蒙娜保护癌症研究所（美国新泽西州劳伦斯维尔）提供.These 17 women had endometriosis (seven),uterine fibroids (three),sinusitis (four),rheumatoid arthritis (two),and ulcerative colitis (one) and were included in the masked validation set.这17名妇女患有子宫内膜异位症（7人）,子宫纤维瘤（3人）,窦炎（4人）,类风湿性关节炎（2人）和溃疡性肠炎（1人）,并被包括在隐蔽的证实组中.Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria:at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer.来自NOCEDP的案例在至少下面的资格标准之一下是自荐的：至少有一个受到影响的直系亲属； 家族性乳腺癌或卵巢癌综合征；BRCA1或BRCA2基因突变阳性；或者个人的乳腺癌史.BRCA1/2 status was not made available to this analysis under the conditions of anonymisation.The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
在anonymisation条件下BRCA1/2状态不能用于此分析.选择高风险人群是因为对于正处于卵巢癌发展高风险中的妇女来说,获得一个有生命力的管理选项特别重要.
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer.Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
所有妇女都接受每年一次的、CA125浓度的三维彩色多普勒超声波检查和测量.6个案例被定义为未受影响的,因为她们至少有5年的随访检查是没有诊断出卵巢癌.带有卵巢癌的案例是符合资格的,条件是她们在被妇科肿瘤医生病例分期之前存有一份血清样本.
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1).All major epithelial subtypes of ovarian cancer were represented,and six of the cancer samples were from women with stage I disease,which mirrors the distribution of stage I ovarian cancer in the community.Reported oral contraceptive use and parity was not different between the groups.在38%的未受影响的妇女中,用超声波图像检测到了简单的卵巢囊肿（表1）.卵巢癌的所有主要的上皮细胞亚型都做了表示,而6个癌的样本来自于患有第一期疾病的妇女,这反映了第一期卵巢癌在公众中的分布.报道的口服避孕药的使用和不均衡在对照组之间没什么差别.The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set.These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]),including only those with stage I cancers (57 [35–75]).On the basis of the age distribution,premenopausal and postmenopausal women were ally represented in both groups,thus menopausal status should not have been a discriminator in the detection algorithm.在初步组中健康的无症状对照人群的中值年龄为49岁(范围21-75) ,而在隐蔽的证实组中为48岁（范围25－73）.这些年纪与初步组中癌症病人的年纪（中值58岁[范围29－82]）和隐蔽的证实组中癌症病人,包括仅为第一期癌症病人的年纪（59[30-80]没有重大差别.在年龄分布的基础上,绝经前和绝经后的妇女都在两个小组中有所代表,所以月经状态应该对检测算法不是鉴别的因素.
Study population
研究人群
100 control samples (50 for the preliminary analysis and 50 for the masked analysis) were provided from the National Ovarian Cancer Early Detection Program (NOCEDP) clinic at Northwestern University Hospital (Chicago,IL,USA).17 other control samples from anonymous women unaffected by cancer were provided by the Simone Protective Cancer Institute (Lawrenceville,NJ,USA).100个对照样本（50个用于初步分析,50个用于隐蔽的分析）由西北大学医院（美国伊利诺斯州芝加哥）的卵巢癌早期检测计划（NOCEDP）的诊所提供.另外17个来自于没有受癌症影响的、姓名不详的妇女的样本则由西蒙娜保护癌症研究所（美国新泽西州劳伦斯维尔）提供.These 17 women had endometriosis (seven),uterine fibroids (three),sinusitis (four),rheumatoid arthritis (two),and ulcerative colitis (one) and were included in the masked validation set.这17名妇女患有子宫内膜异位症（7人）,子宫纤维瘤（3人）,窦炎（4人）,类风湿性关节炎（2人）和溃疡性肠炎（1人）,并被包括在隐蔽的证实组中.Cases from the NOCEDP were self-referred under at least one of the following eligibility criteria:at least one affected first-degree relative; familial breast or ovarian cancer syndrome; positivity for BRCA1 or BRCA2 mutations; or personal history of breast cancer.来自NOCEDP的案例在至少下面的资格标准之一下是自荐的：至少有一个受到影响的直系亲属； 家族性乳腺癌或卵巢癌综合征；BRCA1或BRCA2基因突变阳性；或者个人的乳腺癌史.BRCA1/2 status was not made available to this analysis under the conditions of anonymisation.The high-risk population was chosen because availability of a viable management option is particularly important for women who are at increased risk of development of ovarian cancer.
在anonymisation条件下BRCA1/2状态不能用于此分析.选择高风险人群是因为对于正处于卵巢癌发展高风险中的妇女来说,获得一个有生命力的管理选项特别重要.
All women received a yearly three-dimensional colour doppler flow ultrasound examination and measurement of CA125 concentration.6 Cases were defined as unaffected if they had had a minimum of 5 yearly follow-up examinations without diagnosis of ovarian cancer.Cases with ovarian cancer were eligible if they had had a serum sample banked before pathological staging by a gynaecological oncologist.
所有妇女都接受每年一次的、CA125浓度的三维彩色多普勒超声波检查和测量.6个案例被定义为未受影响的,因为她们至少有5年的随访检查是没有诊断出卵巢癌.带有卵巢癌的案例是符合资格的,条件是她们在被妇科肿瘤医生病例分期之前存有一份血清样本.
Simple ovarian cysts were detected by ultrasonography in 38% of the unaffected women (table 1).All major epithelial subtypes of ovarian cancer were represented,and six of the cancer samples were from women with stage I disease,which mirrors the distribution of stage I ovarian cancer in the community.Reported oral contraceptive use and parity was not different between the groups.在38%的未受影响的妇女中,用超声波图像检测到了简单的卵巢囊肿（表1）.卵巢癌的所有主要的上皮细胞亚型都做了表示,而6个癌的样本来自于患有第一期疾病的妇女,这反映了第一期卵巢癌在公众中的分布.报道的口服避孕药的使用和不均衡在对照组之间没什么差别.The median age in the healthy symptom-free control population was 49 years (range 21–75) in the preliminary set and 48 years (25–73) in the masked validation set.These ages were not substantially different from those for the cancer patients in the preliminary set (median 58 years [range 29–82]) and in the masked validation set (59 [30–80]),including only those with stage I cancers (57 [35–75]).On the basis of the age distribution,premenopausal and postmenopausal women were ally represented in both groups,thus menopausal status should not have been a discriminator in the detection algorithm.在初步组中健康的无症状对照人群的中值年龄为49岁(范围21-75) ,而在隐蔽的证实组中为48岁（范围25－73）.这些年纪与初步组中癌症病人的年纪（中值58岁[范围29－82]）和隐蔽的证实组中癌症病人,包括仅为第一期癌症病人的年纪（59[30-80]没有重大差别.在年龄分布的基础上,绝经前和绝经后的妇女都在两个小组中有所代表,所以月经状态应该对检测算法不是鉴别的因素.